Market revenue in 2023 | USD 27.1 million |
Market revenue in 2030 | USD 74.6 million |
Growth rate | 15.5% (CAGR from 2023 to 2030) |
Largest segment | Product |
Fastest growing segment | Services |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Product, Services |
Key market players worldwide | Thermo Fisher Scientific Inc, Illumina Inc, Qiagen NV, Abcam PLC, Takara Bio Inc, Revvity Inc, Maravai LifeSciences Holdings Inc Ordinary Shares - Class A, HTG Molecular Diagnostics Inc, Meridian Bioscience, New England Biolabs, Norgen Biotek, System Biosciences, Amoy Diagnostics, EntroGen |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to mirna sequencing and assay market will help companies and investors design strategic landscapes.
Product was the largest segment with a revenue share of 80.81% in 2023. Horizon Databook has segmented the China mirna sequencing and assay market based on product, services covering the revenue growth of each sub-segment from 2018 to 2030.
China is one of the key contributors to Asia Pacific's revenue with the fastest growth rate over the forecast period, which can be attributed to the growing population and the resultant increase in healthcare expenditure. China is focusing on developing novel technologies and improving R&D activities to enhance its existing healthcare facilities.
In addition, growth in medical research to develop new miRNA applications is likely to positively impact the market in the country. China has been conducting a lot of research on miRNA sequencing. Lung cancer is one of the primary reasons for deaths in the country. The Chinese government is funding many research projects to develop breakthrough therapies for such life-threatening diseases.
The overall market in the Asia Pacific region is expected to show lucrative growth over the forecast period owing to increasing miRNA sequencing research for therapy and personalized medicine. The aging population along with prevalence of chronic diseases is expected to significantly contribute to the demand for advanced research in China, thereby contributing to growth of the market in the coming years.
Horizon Databook provides a detailed overview of country-level data and insights on the China mirna sequencing and assay market , including forecasts for subscribers. This country databook contains high-level insights into China mirna sequencing and assay market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account